GH Research (NASDAQ:GHRS) rose 6.88% on June 23, 2026, as psychiatric trial publication sustained clinical optimism, with shares closing at $23.61.
Key Highlights
- Rose 6.88%: GH Research closed at $23.61 on June 23 after moving $1.52 per share.
- Catalyst: During the session, psychiatric trial publication sustained clinical optimism.
- Company: GH Research develops mebufotenin-based treatments for depression and other psychiatric disorders.
- Session: The stock finished at $23.61, while the available company record showed a disclosed catalyst for the move.
GH Research (NASDAQ:GHRS) rose 6.88% on June 23, 2026, closing at $23.61 after a $1.52 per-share move. The session’s advance came as psychiatric trial publication sustained clinical optimism, based on the available company disclosures and trading context.
GH Research develops mebufotenin-based treatments for psychiatric disorders, and interest continued following recent peer-reviewed publication of Phase 2a data in postpartum depression as well as scientific presentations at psychiatry conferences. The company's 5-MeO-DMT inhaled formulation candidate is in active clinical development.
GH Research develops mebufotenin-based treatments for depression and other psychiatric disorders.
No additional trial data or FDA interaction was disclosed during the June 23 session. The gain reflected accumulated optimism from the clinical calendar.
The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.
The shares closed at $23.61 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.
For the June 23 close, the defining facts were the 6.88% advance, the $23.61 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.






Please wait processing your request...